World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Long-term treatment of schizophrenia
Peter Falkai,Thomas Wobrock,Jeffrey A. Lieberman,Birte Glenthøj,Wagner F. Gattaz,Hans-Jürgen Möller,Wfsbp Task Force on Treatment Guidelines for Schizophrenia +6 more
Reads0
Chats0
TLDR
These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence.Abstract:
These guide lines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBO). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A-D). This first part of the guidelines covers disease definition, classification, epidemiology and course of schizophrenia, as well as the management of the acute phase treatment. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.read more
Citations
More filters
Journal ArticleDOI
Physical illness in patients with severe mental disorders.I. Prevalence, impact of medications and disparities in health care
Marc De Hert,Christoph U. Correll,Julio Bobes,Marcelo Cetkovich-Bakmas,Dan Cohen,Itsuo Asai,Johan Detraux,S. Gautam,Hans-Jurgen Möller,David M. Ndetei,John W. Newcomer,Richard Uwakwe,Stefan Leucht +12 more
TL;DR: Prevalence rates of different physical illnesses as well as important individual lifestyle choices, side effects of psychotropic treatment and disparities in health care access, utilization and provision that contribute to these poor physical health outcomes are reported.
Journal ArticleDOI
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Christoph Hiemke,Pierre Baumann,Niels Bergemann,Andreas Conca,Otto Dietmaier,Karin Egberts,Miriam Fric,Manfred Gerlach,Christine Greiner,Gerhard Gründer,E Haen,Ursula Havemann-Reinecke,E. Jaquenoud Sirot,H. Kirchherr,Gerd Laux,U. C. Lutz,Thomas Messer,Matthias J. Müller,Bruno Pfuhlmann,Bernhard Rambeck,P. Riederer,Bernd Schoppek,Julia C. Stingl,Manfred Uhr,S. Ulrich,R. Waschgler,Gerald Zernig +26 more
TL;DR: Following guidelines for TDM in psychiatry will help to improve the outcomes of psychopharmacotherapy of many patients especially in case of pharmacokinetic problems, and one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data.
Journal ArticleDOI
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
Oliver D. Howes,Robert A. McCutcheon,Ofer Agid,Andrea de Bartolomeis,Nico J.M. van Beveren,Michael L. Birnbaum,Michael A P Bloomfield,Rodrigo A. Bressan,Robert W. Buchanan,William T. Carpenter,David J. Castle,Leslie Citrome,Zafiris J. Daskalakis,Michael Davidson,Richard J. Drake,Serdar M. Dursun,Bjørn H Ebdrup,Helio Elkis,Peter Falkai,W. Wolfgang Fleischacker,Ary Gadelha,Fiona Gaughran,B. Glenthøj,Ariel Graff-Guerrero,Jaime Eduardo Cecílio Hallak,William G. Honer,James L. Kennedy,Bruce J. Kinon,Stephen M. Lawrie,Jimmy Lee,F. Markus Leweke,James H. MacCabe,Carolyn B. McNabb,Herbert Y. Meltzer,Hans-Jürgen Möller,Shinchiro Nakajima,Christos Pantelis,Tiago Reis Marques,Gary Remington,Susan L. Rossell,Bruce R. Russell,Cynthia Siu,Takefumi Suzuki,Iris E. C. Sommer,David Taylor,Neil Thomas,Alp Üçok,Daniel Umbricht,James T.R. Walters,John M. Kane,Christoph U. Correll +50 more
TL;DR: The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation in schizophrenia.
Journal ArticleDOI
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
Alkomiet Hasan,Peter Falkai,Thomas Wobrock,Jeffrey A. Lieberman,Birte Glenthøj,Wagner F. Gattaz,Florence Thibaut,Hans-Jürgen Möller +7 more
TL;DR: These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005 and provide evidence-based practice recommendations that are clinically and scientifically meaningful.
Journal ArticleDOI
A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia
Stefan Leucht,Katja Komossa,Christine Rummel-Kluge,Caroline Corves,Heike Hunger,Franziska Schmid,Claudia Asenjo Lobos,Sandra Schwarz,John M. Davis +8 more
TL;DR: The findings suggest that some second-generation antipsychotics may be somewhat more efficacious than others, but the limitations of meta-analysis must be considered in tailoring drug treatment to the individual patient.
References
More filters
Journal ArticleDOI
Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.
TL;DR: R risperidone is an effective antipsychotic and anxiolytic agent in schizophrenic patients and clinical improvement, defined a priori as a 20% reduction in total Positive and Negative Syndrome Scale scores at end point, was attained.
Journal Article
Family interventions for mental disorders: efficacy and effectiveness.
TL;DR: This study established family factors as a key variable in achieving stable recovery from severe mental disorders and recommended alternatives to family care for people with serious mental disorders.
Journal ArticleDOI
High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients
Jens D. Rollnik,Thomas J. Huber,Hannu Mogk,Sabine Siggelkow,S. Kropp,Reinhard Dengler,Hinderk M. Emrich,Udo Schneider +7 more
TL;DR: The Brief Psychiatric Rating Scale decreased under active rTMS (p < 0.05), whereas depressive symptoms (BDI) and anxiety (STAI) did not change significantly, suggesting prefrontal rT MS might be effective in the non-pharmacological treatment of psychotic patients.
Journal ArticleDOI
Randomized, double-blind, controlled trial of risperidone Versus clozapine in patients with chronic schizophrenia
TL;DR: Risperidone is at least as effective as an antipsychotic as clozapine, providing a valuable new approach for the treatment of schizophrenia.
Journal ArticleDOI
Amisulpride vs. Risperidone in Chronic Schizophrenia: Results of a 6-month Double-blind Study☆
TL;DR: Amisulpride was significantly superior to risperidone in terms of response and also demonstrated better functional effects and subjective response and both treatments were well tolerated and had a similar low incidence of extrapyramidal symptoms.